2011 Annual Meeting | Contemporary Clinical Issues and Case Studies Plenary Session
| 09:00 AM - 12:00 PM |
Break
|
|
| 09:00 AM - 12:00 PM |
Abstract Presenter: Traditional Risk Factors Play a Minor Role in the Excess Stroke Incidence in African Americans: The Reasons for Geographic and Racial Difference in Stroke (REGARDS) Study
George Howard, PhD |
|
| 09:00 AM - 12:00 PM |
Abstract Presenter: Dissonance in Diagnoses of Dementia Type During Life with Attribution Determined at Autopsy in the Honolulu-Asia Aging Study
Lon R. White, MD |
|
| 09:00 AM - 12:00 PM |
Discussant: Dissonance in Diagnoses of Dementia Type During Life with Attribution Determined at Autopsy in the Honolulu-Asia Aging Study
David S. Knopman, MD, FAAN |
|
| 09:00 AM - 12:00 PM |
Abstract Presenter: The Effectiveness of Amantadine Hydrochloride in Improving Level of Consciousness and Functional Recovery in Patients in the Vegetative or Minimally Conscious State after Traumatic Brain Injury
Douglas I. Katz, MD, FAAN |
|
| 09:00 AM - 12:00 PM |
Discussant: The Effectiveness of Amantadine Hydrochloride in Improving Level of Consciousness and Functional Recovery in Patients in the Vegetative or Minimally Conscious State after Traumatic Brain Injury
Ramon R. Diaz-Arrastia, MD, PhD, FAAN |
|
| 09:00 AM - 12:00 PM |
The 2010 MS Diagnostic Criteria, How to Use Them in a CIS case
Xavier Montalban, MD, PhD, FAAN |
|
| 09:00 AM - 12:00 PM |
Resting-State fMRI in the Differential Diagnosis of Dementia
Michael Greicius, MD |
|
| 09:00 AM - 12:00 PM |
The Advocacy Community and Evidence-Based Therapeutics
Ira Shoulson, MD |
|
| 09:00 AM - 12:00 PM |
Discussant: Traditional Risk Factors Play a Minor Role in the Excess Stroke Incidence in African Americans: The Reasons for Geographic and Racial Difference in Stroke (REGARDS) Study
James F. Meschia, MD, FAAN |
| David S. Knopman, MD, FAAN | Dr. Knopman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for DIAN TU study. The institution of Dr. Knopman has received research support from NIH. |
| George Howard, PhD | Dr. Howard has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bayer. |
| Douglas I. Katz, MD, FAAN | Dr. Katz has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Law firms. The institution of Dr. Katz has received research support from NINDS/NIH. Dr. Katz has received publishing royalties from a publication relating to health care. |
| Ramon R. Diaz-Arrastia, MD, PhD, FAAN | Dr. Diaz-Arrastia has stock in BrainBox, LLC. Dr. Diaz-Arrastia has stock in Nia Therpeutics. The institution of Dr. Diaz-Arrastia has received research support from National Institutes of Health. The institution of Dr. Diaz-Arrastia has received research support from Department of Defense. |
| James F. Meschia, MD, FAAN | The institution of Dr. Meschia has received research support from NINDS. The institution of Dr. Meschia has received research support from NINDS. |
| Michael Greicius, MD | Dr. Greicius has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acelot. Dr. Greicius has stock in SBGneuro. |
| Lon R. White, MD | No disclosure on file |
| Xavier Montalban, MD, PhD, FAAN | The institution of Dr. Montalban has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. The institution of Dr. Montalban has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Merck/ EMD Serono. The institution of Dr. Montalban has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. The institution of Dr. Montalban has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Teva. The institution of Dr. Montalban has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Hoffmann-La Roche. The institution of Dr. Montalban has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Actelion/ Janssen Pharmaceuticals. The institution of Dr. Montalban has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for BMS/ Celgene. The institution of Dr. Montalban has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi/ Genzyme. The institution of Dr. Montalban has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BIAL PD. The institution of Dr. Montalban has received personal compensation in the range of $500-$4,999 for serving as a Consultant for PeerVoice. The institution of Dr. Montalban has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Samsung Biosys. The institution of Dr. Montalban has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Zenas BioPharma. Dr. Montalban has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Actelion/ Janssen Pharmaceuticals. Dr. Montalban has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Montalban has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BMS/ Celgene. Dr. Montalban has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck/ EMD Serono. Dr. Montalban has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Montalban has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Hoffmann-La Roche. Dr. Montalban has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi-Genzyme. The institution of Dr. Montalban has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunic Therapeutics. The institution of Dr. Montalban has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Viatris/ Mylan. The institution of Dr. Montalban has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sandoz. The institution of Dr. Montalban has received research support from Biogen. The institution of Dr. Montalban has received research support from Hoffmann-La Roche. The institution of Dr. Montalban has received research support from Sanofi/ Genzyme. The institution of Dr. Montalban has received research support from Merck/ EMD Serono. The institution of Dr. Montalban has received research support from Novartis. The institution of Dr. Montalban has received research support from Teva Pharmaceuticals. The institution of Dr. Montalban has received research support from Actelion/ Janssen Pharmaceuticals. The institution of Dr. Montalban has received research support from BMS/ Celgene. |
| Ira Shoulson, MD | Dr. Shoulson has received research support from Vaccinex. |